Immunotherapy of pulmonary metastases using monoclonal antibody to T-cell suppressor factor and interleukin 2.
Tumor-induced immune suppression of the host may pose a barrier to successful immunotherapy. A monoclonal antibody (MAb 14-12) able to bind and inhibit murine soluble T-cell suppressor factor was tested for in vivo antitumor activity by treatment of mice bearing three-day established pulmonary metastases of a weakly immunogenic methylcholanthrene-induced fibrosarcoma (MCA 106). Administration intraperitoneally in combination with interleukin 2 (IL-2), a growth factor for activated T lymphocytes, resulted in a significant reduction (60% to 90%) of metastases. Neither IL-2 nor monoclonal antibody alone had significant antitumor effects. This study demonstrates in vivo potentiation of IL-2 antitumor activity with an anti-T-cell suppressor factor and points to possible strategies for clinical application.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000302:isolation & purification / Q000627:therapeutic use*; D003601:Cytotoxicity Tests, Immunologic; D004306:Dose-Response Relationship, Immunologic; D004353:Drug Evaluation, Preclinical; D005260:Female; D005354:Fibrosarcoma / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D007114:Immunization; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary* / Q000628:therapy*; D008748:Methylcholanthrene; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D051381:Rats; D011994:Recombinant Proteins / Q000627:therapeutic use; D013491:Suppressor Factors, Immunologic / Q000276:immunology*
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D011994:Recombinant Proteins; D013491:Suppressor Factors, Immunologic; D008748:Methylcholanthrene